+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 75Years
FEMALE
ID06278870

Comparing Disitamab Vedotin Plus Pyrotinib With Standard THP Treatment for HER2-positive Advanced Breast Cancer in Adults

Led by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Updated on 2024-02-26

312

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of a new combination treatment using disitamab vedotin and pyrotinib compared to the current standard first-line therapy of paclitaxel combined with trastuzumab and pertuzumab for women newly diagnosed with recurrent or metastatic HER2-positive advanced breast cancer. This phase III randomized, double-blind trial also explores how biomarkers might influence treatment outcomes and safety. Participants in the experimental group receive disitamab vedotin intravenously every 14 days at 2 mgkg combined with daily oral pyrotinib in 28-day cycles for 6 to 8 cycles, followed by maintenance treatment with trastuzumab and pyrotinib. The control group receives a taxane drug such as docetaxel or paclitaxel with trastuzumab and pertuzumab every 21 days for 6 to 8 cycles, followed by maintenance therapy with trastuzumab and pertuzumab. Treatment dosing aligns with national guidelines for breast cancer therapy. During the study, participants will have regular assessments including tumor measurements, organ function tests, and quality of life evaluations. Researchers will monitor progression-free survival over about 30 months, along with overall survival, disease control rates, response rates, clinical benefits, adverse events, and biomarker effects. Safety monitoring continues through treatment completion, with the total study duration extending to 8 years for some outcomes.

CONDITIONS

Brief Title

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here